Free tool
FAERS Monitor: Ogsiveo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217677 or its brand name (Ogsiveo, Nirogacestat Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
923
Serious
302
33% of reports
Hospitalization
139
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea323
- nausea203
- fatigue177
- rash120
- product dose omission issue93
- headache90
- vomiting82
- stomatitis61
- cough50
- pruritus48
- alopecia45
- intentional underdose42
- product dose omission in error42
- abdominal discomfort40
- dehydration38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 15 |
| 2023 | 22 |
| 2024 | 563 |
| 2025 | 156 |
| 2026 | 164 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,236 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional underdoseSignal | 42 | 131.8 | 98.0 | 5,292 |
| product dose omission in errorSignal | 42 | 33.8 | 25.2 | 1,306 |
| stomatitisSignal | 61 | 22.9 | 18.0 | 1,261 |
| diarrhoeaSignal | 323 | 11.4 | 10.4 | 3,152 |
| product dose omission issueSignal | 93 | 7.2 | 5.9 | 498 |
| dehydrationSignal | 38 | 6.5 | 4.8 | 172 |
| rashSignal | 120 | 6.3 | 5.3 | 538 |
| nauseaSignal | 203 | 5.8 | 5.2 | 842 |
| abdominal discomfortSignal | 40 | 5.4 | 4.0 | 141 |
| alopeciaSignal | 45 | 5.2 | 3.9 | 151 |
| fatigueSignal | 177 | 5.2 | 4.5 | 616 |
| coughSignal | 50 | 4.1 | 3.1 | 114 |
| vomitingSignal | 82 | 4.0 | 3.2 | 184 |
| headacheSignal | 90 | 3.3 | 2.7 | 144 |
| pruritusSignal | 48 | 2.8 | 2.2 | 57 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.